All In Biotech

Drug Trial Radar · NCT01785290

pRophylactic halopEriDol Use for Delirium in iCu patiEnts With a High Risk for Delirium

Prophylactic Haloperidol Use for Delirium in ICU Patients; a Randomized Placebo-controlled Double-blind Multicentre Trial

Last checked: Nov 20, 2026Latest source record: Nov 12, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 1,800 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,800

Actual

Start

Jun 2013

Primary completion

Dec 2016

Study completion Mar 2017

Sponsor

Lead sponsor
Radboud University Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
ZonMw: The Netherlands Organisation for Health Research and Development
First posted
Feb 7, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Single group
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this study is to determine the effects of a low dosage of prophylactic haloperidol in patients with a high risk to develop delirium, defined by an expected ICU length of stay of \>1 day. The investigators hypothesized that haloperidol prophylaxis in patients with a high risk for delirium reduces 28-day mortality, delirium and delirium related outcome. Two different dosages of haloperidol are used in this study to compare with placebo. A dosage of 1mg, or 2mg or placebo three times a day in a double-blinded fashion resulting in a three-armed multicentre randomized double-blinded placebo-controlled trial. To relate the potential beneficial effects of haloperidol to the a priori risk to develop delirium, the PREDELIRIC-model (delirium prediction model for ICU patients) will be used. This will enable the investigators to determine the preventive efficacy of haloperidol in patient groups based on their risk to develop delirium.

Conditions

  • Delirium

Interventions

  • Haloperidol 1 mg/q8hDrug

    Patients receive prophylactic haloperidol until discharge from the ICU or when delirium occurs. In the latter case study drug will be stopped and patients will be subsequently treated according to the delirium protocol with open-label haloperidol. To avoid unnecessary risk for side-effects the dose will be halved in patients: * aged ≥ 80 years * weight ≤ 50 kg * liver failure Patients with an adjusted dosage of study drug remain allocated to their original group. In case of occurrence of QTc-time prolongation the study drug will be stopped. After normalisation of QTc-time (\<500msec.) the study drug will be restarted. If QTc-time becomes prolonged again, the study drug will be stopped definitively. The patient will remain allocated to the original study group.

  • Haloperidol 2 mg/q8hDrug

    Patients receive prophylactic haloperidol until discharge from the ICU or when delirium occurs. In the latter case study drug will be stopped and patients will be subsequently treated according to the delirium protocol with open-label haloperidol. To avoid unnecessary risk for side-effects the dose will be halved in patients: * aged ≥ 80 years * weight ≤ 50 kg * liver failure Patients with an adjusted dosage of study drug remain allocated to their original group. In case of occurrence of QTc-time prolongation the study drug will be stopped. After normalisation of QTc-time (\<500msec.) the study drug will be restarted. If QTc-time becomes prolonged again, the study drug will be stopped definitively. The patient will remain allocated to the original study group.

  • PlaceboDrug

    Sodium Chloride 0.9%

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. All cause mortalityTime frame: 28-day

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Radboud University Medical Centre

    Nijmegen, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.